上海招聘

？    Manage present Patient Access programs, including tracking project implementation, solving problems, supporting cooperative functions, ensuring in compliance; etc.; and prepare launching new Patient Access programs for innovative medicines;
？    Maintain effective communication with key external and internal parties or stakeholders and develop partnership with potential stakeholders;
？    Identify and create collaboration opportunities with third parties as charity foundations and commercial insurance companies to develop innovative Patient Access Programs;
？    Track policy development, monitor industry practices, formulate patient access strategy in line with BeiGene’s vision and business objectives;
？    Support relevant functions’ work and programs;
职位要求：
？    Working experience from pharmaceutical companies, with 2+ years’ experience in PAP or patient education area;
？    Key competencies including Project management, KOL Engagement, Coordination and Collaboration; Project management experiences is a must-have requirement;
？    Capability of data analyzing, strategy thinking, project designing, industry and policy trend analyzing;
？    Team work and supportive;
？    Result oriented, hardworking, persistent and willing to make extra efforts when needed;
？    Quick learner, open-minded and creative when facing challenges;
？    Stick to the highest requirement for integrity, ethics and compliances;

百济神州是一家植根中国的全球性商业化生物医药公司，致力于成为分子靶向药物和免疫肿瘤药物研发，及商业创新领域的全球领导者。
2017年，百济神州与新基公司达成战略合作伙伴关系，向新基转让了tislelizumab在美国、欧洲、日本和亚洲以外的其他地区的实体瘤开发和商业化的独家权益，保留了在亚洲（除日本外）开发和商业化tislelizumab用于治疗实体瘤的权益，以及用于治疗恶性血液肿瘤和进行内部组合疗法的全球范围权益。

此外，百济神州获得了新基公司在华获批药物——注射用白蛋白紫杉醇（ABRAXANE？）, 瑞复美（REVLIMID？）和 维达莎（VIDAZA？）的独家授权，并接管其在华商业运营团队。

2018年1月，百济与Mirati公司sitravatinib在亚太地区的独家授权协议，进一步拓宽了公司的产品组合。

截至目前，百济神州在全球各地拥有超过1100名员工，其中包括在中国、美国、澳大利亚和瑞士的超过650名科学家及临床医学专家。

公司在中国的北京、上海、美国的马萨诸塞州Cambridge，新泽西州Fort Lee和加利福尼亚州旧金山Emeryville和San Mateo，瑞士的巴塞尔均设有办事机构。除此之外，百济神州在中国大陆还拥有位于北京的研发中心，苏州、广州两大生产基地，以及在上海的商业运营中心。